Literature DB >> 25293789

Activated protein C resistance testing for factor V Leiden.

Stephan Kadauke1, Bernard Khor, Elizabeth M Van Cott.   

Abstract

Activated protein C resistance assays can detect factor V Leiden with high accuracy, depending on the method used. Factor Xa inhibitors such as rivaroxaban and direct thrombin inhibitors including dabigatran, argatroban, and bivalirudin can cause falsely normal results. Lupus anticoagulants can cause incorrect results in most current assays. Assays that include dilution into factor V-deficient plasma are needed to avoid interference from factor deficiencies or elevations, which can arise from a wide variety of conditions such as warfarin, liver dysfunction, or pregnancy. The pros and cons of the currently available assays are discussed.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25293789     DOI: 10.1002/ajh.23867

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.

Authors:  Gianluca Gessoni; Sara Valverde; Letizia Valle; Pierpaolo Caruso; Francesca Gessoni; Roberto Valle
Journal:  Blood Transfus       Date:  2017-03-07       Impact factor: 3.443

2.  A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: impact on management.

Authors:  Chakri Gavva; Ravindra Sarode; Ayesha Zia
Journal:  Blood Adv       Date:  2017-11-22

3.  Interconnectedness of global hemostasis assay parameters in simultaneously evaluated thrombin generation, fibrin generation and clot lysis in normal plasma.

Authors:  Kevin Z Xin; William C Chang; Mikhail V Ovanesov
Journal:  Thromb Res       Date:  2015-11-19       Impact factor: 3.944

4.  Fluorescence artifact correction in the thrombin generation assay: Necessity for correction algorithms in procoagulant samples.

Authors:  William C Chang; Joseph W Jackson; Kellie R Machlus; Alisa S Wolberg; Mikhail V Ovanesov
Journal:  Res Pract Thromb Haemost       Date:  2021-03-26

5.  Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen.

Authors:  Luuk J J Scheres; Nienke L D Selier; Nienke M Nota; Jeske J K van Diemen; Suzanne C Cannegieter; Martin den Heijer
Journal:  J Thromb Haemost       Date:  2021-02-22       Impact factor: 5.824

6.  Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system.

Authors:  Laure Morimont; Charline Leclercq; Marie Didembourg; Émilie De Gottal; Audrey Carlo; Ulysse Gaspard; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Res Pract Thromb Haemost       Date:  2022-04-07

7.  Impact of Inherited Prothrombotic Disorders on the Long-Term Clinical Outcome of Percutaneous Transluminal Angioplasty in Patients with Diabetes.

Authors:  Michal Dubský; Alexandra Jirkovská; Libuše Pagáčová; Robert Bém; Andrea Němcová; Vladimíra Fejfarová; Veronika Wosková; Edward B Jude
Journal:  J Diabetes Res       Date:  2015-07-13       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.